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Abstract 
The ȕ-Lactam antibiotics represent the most successful dug class for treatment of 
bacterial infections. Resistance to them, importantly via production of ȕ-lactamases, which 
collectively are able to hydrolyse all classes of ȕ-lactams, threatens their continued widespread 
use. Bicyclic boronates show potential as broad spectrum inhibitors of the mechanistically 
distinct serine- and metallo- serine (SBL) and metallo (MBL) ȕ-lactamase families. Together 
with reported studies on the structural basis of bicyclic boronate inhibition of  class A, B and 
D ȕ-lactamases, biophysical studies including crystallographic analysis of a bicyclic boronate 
in complex with the clinically important class C AmpC SBL from Pseudomonas aeruginosa 
supports the proposal bicyclic boronates mimic tetrahedral intermediates common to SBL and 
MBL catalysis.  Microbiological studies on the clinical coverage (in combination with 
meropenem) and induction of ȕ-lactamases by bicyclic boronates further support the promise 
of such compounds as broad spectrum ȕ-lactamase inhibitors. 
Keywords: ȕ-Lactamase inhibition, ȕ-lactam antibiotic resistance, cyclic boronate inhibitor, 
metallo and serine ȕ-lactamases, transition state analogue, surface plasmon resonance, ȕ-
lactamase induction, clinical coverage, carabapenem. 
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 Introduction 
The ȕ-Lactam antibiotics represent the most successful dug class for treatment of 
bacterial infections1. Resistance mechanisms, particularly the production of ȕ-lactamases, 
which collectively are able to hydrolyse all the classes of ȕ-lactam antibiotic, endanger their 
continued widespread use2 (Figure 1A). Success has been had in the treatment of bacterial 
infections exhibiting resistance by some serine-ȕ-lactamases (SBLs), particularly Ambler class 
A enzymes, via co-adminstration of a penicillin with a ȕ-lactam based SBL inhibitor, i.e. 
clavulanic acid3-4, sulbactam,5 or tazobactam6. The recent introduction of avibactam, which is 
active against class A, C, and some class D ȕ-lactamases, demonstrates the viability of non ȕ-
lactam based ȕ-lactamase inhibition and is an important step in more broadly combating SBLs7. 
Acyclic boronic acids have long been known to inhibit nucleophilic enzymes, including SBLs8-
9
 (Figure 1B). In co-administration with meropenem the (predominantly) monocyclic boronic 
acid, vaborbactam (Figure 1C), has been introduced for treatment of complicated urinary tract 
infections (cUTI)10. Vaborbactam is relatively potent in inhibiting class A SBLs, including the 
KPC carbapenemases, but is not active against MBLs and, at least, some clinically relevant 
SBLs10. 
 
 
 
Figure 1. A) Outline mechanisms of serine- and metallo-ȕ-lactamase (SBL and MBL) 
catalysis, exemplified with a cephalosporin. Note products can be produced in different 
tautomeric forms. The tetrahedral intermediate, common to both SBLs and MBLs, may be 
mimicked by cyclic boronates. B) Structures of Vaborbactam and bicyclic boronate ȕ-
lactamase inhibitors VNRX-5133, 1 and 2. 
 
By contrast with the SBLs, to date there are no clinically useful inhibitors of the 
metallo-ȕ-lactamases (MBLs, Ambler class B)11, which are structurally and mechanistically 
distinct from the SBLs and which are structurally heterogeneous (B1-3 MBL subfamilies)12 
(Figure 1A). The ability of the MBLs to hydrolyse ȕ-lactam based SBL inhibitors prohibits 
their use against bacteria producing both MBLs and SBLs12. The observation that MBLs can 
bind and hydrolyse avibactam, albeit slowly13, as well as SBL-mediated resistance to avibactam 
suggests that the future use of avibactam will be jeopardised by ȕ-lactamases1314. Thus the 
development of dual-action SBL and MBL ȕ-lactamase inhibitors is of interest. 
We have reported that boronates with a (at least predominantly, in solution) bicyclic 
scaffold are able to inhibit representatives of all four Ambler classes15-17. These inhibitors are 
proposed to mimic the tetrahedral intermediates in ȕ-lactam hydrolysis common to both SBLs 
and MBL15-16. We now report a crystal structure of a bicyclic boronate in complex with the 
clinically important class C AmpC ȕ-lactamase from Pseudomonas aeruginosa. Together with 
reported studies on the structural basis of bicyclic boronate inhibition of class A, B and D ȕ-
lactamases and other biophysical analyses our results support the proposal that bicyclic 
boronates mimic the tetrahedral intermediates common to both serine- and metallo-ȕ-lactamase 
hydrolysis. Microbiological studies on the clinical coverage (in combination with meropenem) 
and induction of ȕ-lactamases by bicyclic boronates validate the potential of such compounds 
as broad spectrum ȕ-lactamase inhibitors. 
 
Experimental Procedures 
Enzyme production 
Recombinant VIM-2, with an N-terminal His-tag, was produced using the reported pOPINF 
construct18 in E. coli BL21(DE3) pLysS cells using 2TY medium supplemented with ȝJP/-
1
 DPSLFLOOLQDQGȝJP/-1 chloramphenicol. Cells were grown until an OD600 of 0.6 ± 0.7 was 
reached before cooling to 30 °C; expression was induced with iVRSURS\O ȕ-D-1-
thiogalactopyranoside (0.5 mM final concentration). The cells were then incubated for a further 
four hours at 30 °C. Recombinant AmpC from P. aeruginosa15, with an N-terminal His-tag, 
was produced in E. coli BL21(DE3) cells using auto-induction medium supplemented with 50 
ȝJ P/-1 ampicillin. Cells were grown for four hours at 37 °C before cooling to 18 °C and 
continuing growth overnight.  
Cells were harvested by centrifugation (10 min, 10000 g), resuspended in 50 mL lysis 
buffer (50 mM HEPES, pH 7.5, 500 mM NaCl, 5 mM imidazole), supplemented with DNAse 
I, then lysed by sonication. The supernatant was loaded onto a 5 mL HisTrap HP column 
followed by extensive washing with 50 mM HEPES, pH 7.5, 500 mM NaCl, 5 mM imidazole, 
EHIRUH HOXWLRQZLWKDíP0LPLGD]ROHJUDGLHQW)UDFWLRQVFRQWDLQLQJSXULILHG HQ]\PH
were concentrated by centrifugal ultrafiltration (Amicon Ultra -15 mL, 10 kDa MWCO, 
Millipore). The resultant solution was injected onto a Superdex S200 column (300 mL) and 
eluted with 50 mM HEPES, pH 7.5, 200 mM NaCl. For AmpC and VIM-2, fractions containing 
pure His-tagged enzyme were incubated overnight at 4 °C with His-tagged 3C protease (1:100 
w/w) to remove the N-terminal His-tag. The 3C protease together with any uncleaved protein 
the digestion mixture was removed by use of a second HisTrap HP column pre-equilibrated 
with 50 mM HEPES, pH 7.5, 500 mM NaCl, 20 mM imidazole. Chromatography employed 
using ÄKTAFPLC machine. 
Purified enzyme containing fractions, as identified by SDS-PAGE, were pooled and 
concentrated by centrifugal ultrafiltration, then buffer exchanged into 25 mM HEPES, pH 7.5, 
100 mM NaCl. The concentrations of the purified proteins were determined using a NanoDrop 
ND-1000 spectrophotometer (Thermo Scientific, İ = 61310, or 31400 M-1 cm-1 for AmpC, or 
VIM-2, respectively). 
 
Crystallisation Experiments, X-ray Data Collection and Processing 
Crystallisation experiments were set up using a 18 mg mL-1 solution of AmpC in 50 mM 
HEPES, pH 7.5, 100 mM NaCl supplemented with 10 mM 1. 1 and 2 were prepared as 
reported16. Crystallisation was performed at room temperature using the sitting drop vapour 
diffusion method. Crystals were obtained after approximately five months using 100 ȝL 
reservoir solution comprised of 200 mM Zn(OAc)2.2H2O, 100 mM imidazole, 20% PEG 3000, 
pH 8.0 and a 1:1 mixture (0.2 ȝL:0.2 ȝL) of protein to reservoir solution in the crystallisation 
drop. Crystals were cryo-protected using 25% glycerol in reservoir solution before harvesting 
with nylon loops and flash-cooling in liquid nitrogen. Diffraction data were collected at 100 K 
on beamline I04 of the Diamond Light Source, Didcot. Diffraction data were integrated and 
scaled using autoPROC. The structure was solved by isomorphous replacement using a 
published structure (PDB accession code: 4WYY) as a search model. The structure was then 
fit and refined iteratively using PHENIX20 and Coot21. 
 
 
 
Surface Plasmon Resonance 
A GE Healthcare Biacore T200 machine was used for all SPR experiments. The temperature 
was kept at 4 oC to increase stability of the protein on the chip. VIM-2 was µminimally¶ 
biotinylated, i.e. protein was incubated with EZ link NHS-LCLC-Biotin (succinimidyl-6-
(biotinamido)-6-hexanamido hexanoate, ThermoScientific) at a 1:1 ratio for 2 hours at 4 oC; the 
excess of biotin was removed using a desalting column. The modified VIM-2 was attached to 
the streptavidin coated surface of the sensor chip in running buffer: 50 mM Hepes (pH 7.4), 
150 mM NaCl, 0.05% (v/v) Tween 20, 3% (v/v) DMSO at ~ 3000 RU. The boronate inhibitor 
was screened at concentrations ranging from 45 nM ± 3.7 uM, injecting from the lowest to 
highest concentrations. Kinetics were fitted using a 1:1 binding model with local Rmax for each 
concentration due to saturation of the surface.ref Data with the inhibitors were referenced to 
those for a blank surface and blank injections to normalize for non-specific binding and drift. 
A DMSO calibration was run to remove excluded volume effect of binding responses between 
reference and target surface. ref Binding was assayed at pH 6.5, 7.5 and 8.5 in 50 mM Hepes. 
 
ȕ-Lactamase Induction Experiments 
Induction experiments were carried out as described22. In brief, cell cultures were grown 
overnight using nutrient broth and used to inoculate (1:100 dilution) 10 mL nutrient broth 
cultures. Cultures were incubated for 2 h with shaking at 37 °C before addition of potential 
inducers and growth for a further 2 h. Cells were pelleted by centrifugation (4000 g, 10 min) 
and were treated with 100 µL of BugBuster (Ambion). Cell debris was pelleted by 
centrifugation (13,000g, 5 min). Protein concentrations in the supernatant were determined 
using a BioRad protein assay reagent concentrate, according to the manufacturer's instructions. 
ȕ-lactamase activity was determined using an Omega Fluostar (BMG Biotech) using 
meropenem as substrate. 
 
Antimicrobial Susceptibility Testing 
MICs were determined and interpreted for meropenem both alone, and in combination with 2 
(10 Pg/ml), by EUCAST/CLSI guidelines, in line with previously reported data23. 
 
Results 
To investigate the structural basis of class C ȕ-lactamase inhibition by bicyclic 
boronates we co-crystallised recombinant AmpC from P. aeruginosa in complex with bicyclic 
boronate 1. Although crystals were only obtained after months, the overall fold of the AmpC-
boronate 1 complex structure is very similar to that of an apo-AmpC structure (PDB accession 
code: 4GZB), with an RMSD of 0.325 Å over atoms in the peptide backbone and 0.251 Å for 
the residues interacting with the inhibitor at the active site. Analysis of non-protein electron 
density at the AmpC active site reveals that the bicyclic core of boronate 1 is intact and binds 
to AmpC via reaction of the nucleophilic serine (Ser90) with the boron of 1 to give a tetrahedral 
species. As observed with AmpC-Relebactam complex crystal structures, the amide nitrogen 
and carbonyl group of the aminoacyl side chain are positioned to make hydrogen bonding 
interactions with active site  residues (Gln146, Asn179 and Ser345),24 while the saturated 
boracyclic ring is positioned beside tyrosine (Tyr249) and valine (Val239) apparently making 
hydrophobic interactions. The carboxylate group of 1 is directed towards the positively charged 
Lys342, while forming additional hydrogen bonding interactions with Thr343 and Asn373 
(Figure 2), i.e. it binds in a similar manner to that predicted for the analogous carboxylates of 
AmpC/ class C ȕ-lactamase substrates25-26. 
 
Figure 2: Structural basis of serine- and metallo-ȕ-lactamase inhibition by cyclic boronates. The 
figure shows views from crystal structure of cyclic boronate 1/2 in complex with representatives from 
all four FODVVHVRIȕ-lactamases (A to D). A) and E) Comparison of the binding modes of 1 (PDB ID: 
5T66) and Vaborbactam (PDB ID: 4XUZ) observed with CTX-M-15. B) and D) View from a crystal 
structure of cyclic boronate 2 in complex with VIM-2 (PDB ID: 5FQC) and cyclic boronate 1 in complex 
with OXA-10 (PDB ID: 5FQ9). C) and F) View from a crystal structure of cyclic boronate 1 in complex 
with AmpC (PDB ID: 6I30). Representative electron density for 1 is shown (3.0 ı mFo-DFc OMIT, red 
mesh). 
 
The bicyclic core of 1 binds to AmpC in a remarkably similar conformation / mode to 
that observed for the class A (CTX-M-15 and L2) and D (OXA-10) SBLs (Figure 2), i.e. via 
formation of a likely anionic tetrahedral species formed via reaction of the active site 
nucleophilic serine with the boron of 1 to produce a complex mimicking that proposed in ȕ-
lactamase mediated hydrolysis of bicyclic ȕ-lactams15-16, 22. The binding of the aryl carboxylate 
is similar in all cases, with differences reflecting the different residues involved in binding this 
substrate element in the different SBL types. A similar binding mode, including with respect to 
the observation of a tetrahedral boron has also been observed for 1/2 when complexed with 
PBP5 from Escherichia coli16, though note that the tested bicyclic boronates tend to be much 
weaker PBP inhibitors (and antibiotics) than ȕ-lactamase inhibitors15-16 Thus, a conserved mode 
of binding is observed for bicyclic boronates with all three Ambler classes of serine-ȕ-
lactamase and, at least, one penicillin binding protein (PBP-5). Although, there are differences 
in the active site chemistry of the SBLs and MBLs, crystallographic analyses on the class B1 
MBLs BcII and VIM-215-16 show that the conformation of the biyclic boronate 2 as observed in 
SBLs (and PBP5) is also maintained in binding to these clinically relevant MBLs15-16 (Figure 
2). 
An overlay of our AmpC:1 structure with a structure of AmpC from Enterobacter cloacae in 
complex with the µmonocyclic¶ boronate SBL inhibitor Vaborbactam (4XUX, Supplementary 
Figure S1)27 indicates similar binding modes for the two compounds with their carboxylates 
groups being similarly positioned to interact with Lys342/335, Thr343/336 and Asn373/366, 
and the aminoacyl sidechain adopting similar conformations. The same relative positioning of 
the boron centre and a carboxylate moiety is seen in two structures of AmpC from P. 
aeruginosa in complex with 4,5-disubstituted oxaboroles (4WYY and 4WZ4)28, although the 
aromatic carbocycle is oriented differently in these cases, likely due to the differently 
positioned carboxylate moiety in these molecules. 
 
Reaction of an sp2 boron, or substitution of an sp3 B-OH, with the nucleophilic serine is 
necessary to form the crystallographically observed tetrahedral (sp3) complex in the case of the 
SBLs/PBPs. However, for the MBLs either the sp2 or sp3 forms of the inhibitor could be 
envisaged to bind. To investigate binding of 2 to an MBL in solution, we used surface plasmon 
resonance (SPR) with the clinically relevant B1 MBL VIM-2. Data were collected at pH 6.5, 
7.5, and 8.5 (Figure 3A and Supplementary Figure S1). The affinity of 2 for VIM-2, as 
measured by the KD, varies by a10 fold with pH, with the lowest KD  at pH 6.5 (4.97 nM) and 
a highest at pH 8.5 (55.3 nM), with the differences principally being due to changes in the 
association rate (kon). At least in part this may reflect a bias to the sp2 rather than the sp3 
hybridisation states of the boron of the inhibitor at lower pH29, though other factors including 
potential ring opening/closing of the inhibitor (Figure 1B) and the ȕ-lactamase protonation state 
may be relevant, these observations are consistent with the sp2 form of the inhibitor reacting 
with the zinc ion activated hydrolytic water / hydroxide at the VIM-2 active site.  
 
Treatment of bacteria with ȕ-lactam antibiotics can induce expression of chromosomal genes 
for ȕ-lactamases, for example AmpC enzymes30. This upregulation can arise as a result of 
signalling due to inhibition of cell wall biosynthesis by ȕ-lactam antibiotics30. Administration 
of all clinically used ȕ-lactamase inhibitors results in upregulated ȕ-lactamase production2, 31, 
hence E-lactamase inhibitors that do not induce such an effect may useful in a clinical setting. 
We have reported that both 2 and avibactam do not manifest detectable ȕ-lactamase induction 
in S. maltophilia22. Recent reports have demonstrated that the non ȕ-lactam, but serine 
modifying inhibitor, avibactam can induce the AmpC ȕ-lactamase in Enterobacteriaceae, 
including E. cloacae and some P. aeruginosa31. Thus, we investigated the effects of 2, which 
has a different mode of action, on ȕ-lactamase induction in E. cloacae and P. aeruginosa. As 
anticipated22, 31, with both E. cloacae and P. aeruginosa treatment with a cephalosporin, 
carbapenem, or clavulanic acid results in an increased production of ȕ-lactamases even at 10 
ȝg mL-1 (Figure 3B). By contrast, avibactam or 2 GRHV QRW LQGXFH ȕ-lactamase production 
within limits of detection with either P. aeruginosa or E. cloacae even at a 50 ȝg mL-1 (Figure 
3). 
 
 
 
Figure 3: Binding and microbiological studies with 2. A) Fitted constants for the binding of 2 to VIM-
2 as determined by SPR.; B) ,QGXFWLRQRIȕ-lactamase production by cephalosporins, carbapenems and 
UHSUHVHQWDWLYHȕ-lactamase inhibitors as measured by relative activity. (PAO ± Pseudomonas aeruginosa  
and  EB ± Enterobacter cloacae); C) MIC50/90s of Antimicrobial Test Panel  vs Ambler Class B (Metallo) 
ȕ-Lactamases-producing Enterobacteriaceae by Species (MEM ± meropenem). 
 
We then investigated the activity of 2 in combination with meropenem against contemporary, 
clinical NDM (n=104) and VIM-positive (n=28) Enterobacteriaceae, because these B1 MBLs 
catalyse the hydrolysis of a broad range of ȕ-lactams, including carbapenems (not 
monobactams). 2 significantly improved the rates of meropenem susceptibility (MIC d 2 Pg 
mL-1) against MBL-positive Enterobacteriaceae. Meropenem susceptibility rates of MBL-
positive E. coli with and without 2 were 8% and 64% respectively (Figure 3C and Figures S3-
5). The corresponding susceptibility rates for MBL-positive Klebsiella pneumoniae were 8% 
and 55% respectively. NDM-1-positive A. baumannii (n=3) and VIM-positive P. aeruginosa 
(n=2) were also tested; 2, however, did not induce an MIC shift for meropenem in this case.  
 
 
Conclusions 
 
Boronic acids have been known to inhibit SBLs since the 1970s32 and have a much longer 
history as antibaterials (since 1880s)33. Vaborbactam, an inhibitor of class A, C, and some class 
SBLs, has been introduced for clinical use; however, there is, at present no clinically available 
MBL inhibitors based on the boronic acid chemotype. Bicyclic boronates of the type 
characterised here and in our previous work15-16, 22 hold potential as broad spectrum SBL/MBL 
inhibitors. Together, with work on CTX-M-15, L2, BcII, VIM-2 and OXA-10 ȕ-lactamases15-
16, 22
 the crystallographic work presented here on AmpC, a commonly expressed class C ȕ-
lactamase in resistant P. aeruginosa-based infections, reveals that it is possible to inhibit 
(representative) ȕ-lactamases from all four Ambler classes by a single compound type operating 
via a common mechanism, i.e. mimicking the tetrahedral intermediate common to SBLs and 
MBLs. Moreover, comparison of our AmpC:1 structure with that of Vaborbactam with 
AmpC27, reveals highly similar binding modes for the boron containing ring, aryl-carboxylate, 
and N-acetamido acid chain. 
Given the clear differences in spectrum of activities for Vaborbactam and biyclic 
boronates, with the latter in general appearing better in vitro, there appear to be scope for 
improving the activity of boronates by extending the rather limited SAR reported to date (at 
least compared to the enormous studies on ȕ-lactam antibiotics / ȕ-lactamase inhibitors). The 
bicyclic boronates studied here and in our prior work closely resemble VNRX-513334 (Figure 
1C), which has not been profiled for MBL coverage. Further studies on the precise binding 
modes of the boronates to ȕ-lactamases and PBPs are of interest, including with respect to 
increasing their potency versus PBPs and broadening the scope of MBL inhibition (our 
compounds show only limited inhibitory activity against certain MBLs, including IMP-1, SPM-
1, CphA, and L11622. Our preliminary studies suggest that binding to both SBLs and MBLs may 
involve the sp2 inhibitor form (Figure 1B), again reinforcing the proposed similarity (20,21) in 
binding mode of the bicyclic boronates for SBLs and MBLs.  
 
SBL inhibition by clavulanic acid and related E-lactams (tazobactam, sulbactam) is proposed 
to occurs via acy-enzyme fragmentation resulting in inactivation35. By contrast, avibactam, 
inhibits SBLs via reversible covalent binding35. As revealed by crystallography, the binding 
modes of bicyclic boronates, resemble those of intermediates an route to the acyl-enzyme 
complexes formed with ȕ-lactam antibiotics. The boronate inhibitors also exist as an 
equilibrium between sp2/sp3 states. Thus, it is unclear to what extent borontes will mirror ȕ-
lactams in terms of their ȕ-lactamase inducing capacity. Our results show that 2 does not induce 
ȕ-lactamase production within detection limits in the tested organisms at up to 50 ȝg mL-1. By 
contrast, avibactam induces ȕ-lactamase production in some P. aeruginosa but not in E. 
cloacae31. The lack of induced ȕ-lactamase production by 2, and potentially other boronates, 
may in part reflect the good clinical coverage observed with co-dosing of 2 with meropenem, 
which clearly increases the meropenem susceptibility against MBL-positive 
Enterobacteriaceae. Further structure activity relationship work on the ability of ȕ-lactamases 
inhibitor templates to induce b-lactamases are thus of interest. 
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